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ABSTRACT
Objective Knowledge on severe acute respiratory 
syndrome coronavirus 2 (SARS- CoV-2) infection in liver 
transplant recipients is lacking, particularly in terms 
of severity of the disease. The aim of this study was to 
describe the demographic, baseline clinical characteristics 
and early outcomes of a European cohort of liver 
transplant recipients with SARS- CoV-2 infection.
Design We conducted an international prospective 
study across Europe on liver transplant recipients with 
SARS- CoV-2 infection confirmed by microbiological 
assay during the first outbreak of COVID-19 pandemic. 
Baseline characteristics, clinical presentation, 
management of immunosuppressive therapy and 
outcomes were collected.
Results 57 patients were included (70% male, 
median (IQR) age at diagnosis 65 (57–70) years). 21 
(37%), 32 (56%) and 21 (37%) patients had one 
cardiovascular disease, arterial hypertension and diabetes 
mellitus, respectively. The most common symptoms 
were fever (79%), cough (55%), dyspnoea (46%), 
fatigue or myalgia (56%) and GI symptoms (33%). 
Immunosuppression was reduced in 22 recipients (37%) 
and discontinued in 4 (7%). With this regard, no impact 
on outcome was observed. Forty- one (72%) subjects 
were hospitalised and 11 (19%) developed acute 
respiratory distress syndrome. Overall, we estimated 
a case fatality rate of 12% (95% CI 5% to 24%), 
which increased to 17% (95% CI 7% to 32%) among 
hospitalised patients. Five out of the seven patients who 
died had a history of cancer.
Conclusion In this European multicentre prospective 
study of liver transplant recipients, COVID-19 was 
associated with an overall and in- hospital fatality rate 
of 12% (95% CI 5% to 24%) and 17% (95% CI 7% 
to 32%), respectively. A history of cancer was more 
frequent in patients with poorer outcome.
INTRODUCTION
Severe acute respiratory syndrome coronavirus 2 
(SARS- CoV-2) is a virus belonging to the Orthocoro-
navirinae subfamily, first identified in Wuhan, Hubei 
Province, China, in December 2019.1 Infection with 
SARS- CoV-2 is responsible for a clinical condition, 
named COVID-19, which ranges from mild respira-
tory and/or GI symptoms to interstitial pneumonia 
with acute respiratory distress syndrome (ARDS), 
diffuse thrombotic and thromboembolic disease,2 
multiorgan failure (MOF) and even death with a 
case fatality rate ranging from 5.65%3 to 15%,4 5 
with high geographical heterogeneity. The outbreak 
of SARS- CoV-2 infection, declared pandemic on 11 
March 2020 by the WHO,6 has rapidly become a 
public health matter with several unmet issues. To 
date, firm knowledge on disease evolution, risk 
factors, clinical manifestations and optimal manage-
ment are lacking, particularly in specific categories 
of patients. In the setting of solid organ transplan-
tation, and particularly liver transplant recipients, 
Significance of this study
What is already known on this subject?
 ► Recipients of liver transplantation can be 
infected with SARS- CoV-2.
 ► The outcome of COVID-19 of these 
immunosuppressed patients is not well known.
What are the new findings?
 ► In our European cohort of liver transplant 
patients, overall and in- hospital fatality rates 
were 12% (95% CI 5% to 24%) and 17% (95% 
CI 7% to 32%), respectively. All deaths occurred 
in hospitalised patients.
 ► Immunosuppressants were not discontinued in 
the vast majority of liver transplant recipients 
with COVID-19 infection.
How might it impact on clinical practice in the 
foreseeable future?
 ► Patients infected in the first year after 
transplantation are presenting with less 
symptoms.
 ► A history of cancer was more frequent in liver 
transplant recipient with poorer outcome, 
suggesting that higher attention should be paid 
in these patients.
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information on natural history of COVID-19 are limited to 
expert statements,7 8 case reports9 and small case series.10 11 
Concerns have been raised about immunosuppression therapy, 
and it is still unknown whether the latter actually represents an 
increased risk for more severe illness, including higher risk of 
bacterial coinfection,12 13 or not. In this view, previous expe-
rience with similar viruses, such as SARS- CoV in 200314 and 
MERS- CoV in 2015,15 suggests that solid organ recipients would 
be prone to have increased morbidity.16 However, in these cases, 
sample size and data quality did not allow definitive conclusion. 
Moreover, recent evidence has shown SARS- CoV-2 associated 
liver injury,17–19 which might per se impair the prognosis of liver 
transplant patients with COVID-19. Overall, liver transplant 
patients are a population with multiple potential risk factors for 
poorer outcome that need to be investigated in detail.
This study describes the demographics, baseline clinical char-
acteristics and early outcomes of a European cohort of liver 
transplant recipients with SARS- CoV-2 confirmed infection 
during the first outbreak of COVID-19 pandemic.
Figure 1 Flowchart of the study design.
Table 1 Demographic characteristics of liver transplant recipient 
with SARS- CoV-2 infection
Study population Results
Patients, n 57
Sex, male, n (%) 40 (70)
Ethnicity, Caucasian, n (%) 53 (93)
Age, years, median (IQR) 65 (57–70)
  Age ≥65, n (%) 29 (51)
  Age <65, n (%) 28 (49)
BMI, kg/m2, mean (SD) 26.0±4.6
BMI, classes, n (%)   
  18–24.9 23 (43)
  25–29.9 23 (43)
  >30 8 (14)
Time from transplant to diagnosis, years, median (IQR) 6 (2–13)
  Very long- term transplant recipients, n (%)   21 (37)
  Very short- term transplant recipients, n (%) 11 (19)
  Long- term transplant recipients, n (%) 32 (56)
Indication to LT, n (%)   
  End- stage liver disease 38 (68)
  Liver tumour 16 (29)
  Acute liver failure 4 (7)
  Other 9 (16)
Underlying liver disease, n (%)   
  ALD 15 (26)
  Viral 24 (42)
   HCV 11 (19)
   HBV 13 (23)
  PSC 3 (5)
  PBC 4 (7)
  NAFLD/NASH 2 (4)
  Autoimmune 1 (2)
  Hemochromatosis 1 (2)
  Wilson’s disease 1 (2)
  Other 10 (18)
HCC, yes, n (%) 20 (35)
Comorbidities, n (%)   
  Cardiovascular disease 21 (37)
   Coronary artery disease 7 (12)
   Heart failure 9 (16)
   Atrial fibrillation 6 (11)
   Stroke 1 (2)
   Other 8 (14)
   >1 cardiovascular disease 10 (18)
  Arterial hypertension 32 (56)
  Diabetes mellitus 21 (37)
  Active cancer 5 (9)
  Kidney insufficiency 16 (28)
  Respiratory disease 13 (23)
   COPD 7 (12)
   HIV 1 (2)
Smoke history, yes, n (%) 7 (12)
Symptoms at presentation, n (%)   
  Fever 44 (79)
  Cough 31 (55)
  Dyspnoea 26 (46)
  Fatigue and myalgia 32 (56)
  GI symptoms 18 (33)
   Diarrhoea 16 (28)
   Abdominal pain 1 (2)
   Vomiting 1 (2)
  Anosmia or dysgeusia 4 (7)
Continued
Study population Results
  Other 8 (14)
Concomitant bacterial infection, n (%) 9 (16)
  Suspected 3 (6)
  Confirmed 6 (11)
ALD, alcoholic liver disease; BMI, body mass index; COPD, chronic obstructive pulmonary disease; HCC, 
hepatocellular carcinoma; LT, liver transplantation; NAFLD, non- alcoholic fatty liver disease; NASH, non- 
alcoholic steatohepatitis; PBC, primary biliary cholangitis; PSC, primary sclerosing cholangitis.
Table 1 Continued




We conducted a European multicentre prospective cohort 
study recruiting consecutive liver transplant recipients from 19 
secondary and tertiary (with more than 100 patients in regular 
follow- up) liver transplant centres across Europe. The coordi-
nating centre was the Inselspital, University Hospital of Berne 
(KEK Approval Project ID 2020-00682). Written informed 
consent was obtained from all the included patients. The recruit-
ment was conducted from 10 March to 10 May 2020.
Study population
Consecutive adult (aged >18 years at the time of SARS- CoV-2 
infection) liver transplant recipients with concomitant confirmed 
SARS- CoV-2 infection were included in the study. The defini-
tion of confirmed SARS- CoV-2 infection was made according to 
the WHO guidelines and based on the presence of a laboratory 
assay proving SARS- CoV-2 infection, irrespective of clinical 
signs and symptoms of the disease.20 Nucleic acid amplification 
test (NAAT) positive for SARS- CoV-2 in nasopharyngeal swab, 
sputum samples and bronchoalveolar lavage (BAL) was consid-
ered diagnostic. Typical radiological findings included bilateral, 
peripheral, consolidation and/or ground glass opacities, detected 
by using chest X- ray or thorax- CT scan.21
Patients were enrolled in the study at the time of diagnosis 
of COVID-19 and were followed up until death or 10 May 
2020.
Baseline information regarding indication to liver transplan-
tation, underlying liver disease and comorbidities, as well as 
anthropometric data were collected. At the time of COVID-19 
diagnosis, clinical features and laboratory parameters were 
recorded. All laboratory and imaging investigations were 
performed as part of standard care of patients. Information 
on management of baseline immunosuppression, namely, its 
Table 2 Differential distribution of symptoms between long- term and short- term liver transplant patients
Symptoms,
n (%) Overall
Long- term transplant recipient
P value
Very- short term transplant recipient
P valueNo Yes Yes No
Sex, male 40 (70) 19 (48) 21 (53) 0.561 10 (25%) 30 (75%) 0.146
Age, years, median (IQR) 65 (57–70) 59 (53–65) 68 (61–76) <0.001 55 (52–70) 65 (59–72) 0.058
BMI, kg/m2, mean (SD) 26.0±4.6 26.1±4.6 25.7±5.1 0.563 26.8±5.7 25.3±3.6 0.043
Fever 44 (79) 15 (63) 29 (91) 0.005 6 (55) 38 (84) 0.045
Cough 31 (55) 11 (46) 20 (63) 0.280 3 (27) 28 (62) 0.048
Dyspnoea 26 (46) 7 (29) 19 (59) 0.032 3 (27) 23 (51) 0.192
Fatigue 32 (56) 11 (44) 21 (66) 0.117 4 (36) 28 (61) 0.184
Conjunctivitis 0 – – – – – –
Anosmia/dysgeusia 4 (7) 0 4 (13) 0.131 0 4 (9) 0.573
GI 18 (33) 6 (25) 12 (38) 0.394 1 (9) 17 (38) 0.084
Other 8 (14) 3 (13) 5 (16) 1.000 1 (9) 7 (16) 1.000
Table 3 Initial laboratory data of liver transplant recipient with SARS- CoV-2 infection
Patients tested, n (%) Results
Patients with value, n
Deviation from reference (%)
Blood counts, median (IQR)
  Leucocytes (×1000/μL) 51 (90) 4.50 (3.33–6.00) 17 (33)*
  Platelets (×1000/μL) 49 (86) 160 (91–268) 17 (35)*
  Lymphocytes (×1000/μL) 49 (86) 0.79 (0.40–1.10) 37 (76)*
Biochemical and liver- related test, median (IQR)
  AST (U/L) 49 (86) 38 (25–53) 13 (26)†
  ALT (U/L) 49 (86) 30 (20–42) 10 (20)†
  GGT (U/L) 45 (79) 66 (39–161) 29 (64)†
  ALP (U/L) 37 (65) 97 (74–171) 9 (24)†
  Total bilirubin (mg/dL) 43 (75) 0.70 (0.48–1.09) 10 (23)†
  INR (ratio) 42 (74) 1.10 (1.03–1.28) 14 (33)†
  Albumin (g/L) 19 (33) 32 (29.5–36.5) 8 (42)*
  Creatinine (mg/dL) 50 (88) 1.16 (0.93–1.55) 20 (40)†
  Glucose (mg/dL) 36 (63.2) 127.5 (92.5–163.0) 24 (67)†
Inflammatory- related markers, median (IQR)
  D- Dimer (ng/mL) 17 (29.8) 871 (380–1739) 10 (59)†
  LDH (U/L) 31 (54.4) 273 (192–384) 20 (65)†
  IL-6 (pg/L) 9 (15.8) 93 (59–288) –
  Ferritin (ng/mL) 13 (22.8) 567 (171–1194) 9 (69)†
*Below reference.
†Above reference.
ALP, alanine alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma- glutamyltransferase; IL-6, interleukin-6; INR, international 
normalised ratio; LDH, lactate dehydrogenase.
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reduction or discontinuation, as well as specific pharmacological 
therapies and ventilation support, were obtained.
Patients were classified according to the severity of COVID-19 
disease in outpatient care and hospitalisation, respectively.13 Time 
from liver transplantation was classified as very long term (more 
than 10 years from liver transplant)10 and very short term (1 year 
or less from liver transplant), whereas the terms long and short 
term were adopted if the patients had been transplanted for more 
or less than 5 years, respectively.22 Management of single immuno-
suppression therapy was classified as follows: no change, reduction 
or discontinuation. For patients on double immunosuppression, 
reduction was defined as reduction of at least one immunosuppres-
sive drug and/or discontinuation of one medication, while discon-
tinuation was defined as discontinuation of both drugs.
The main outcome was patient death, while secondary outcomes 
were ARDS diagnosis23 and hospitalisation. All the data were 
entered in an electronic dataset using a standardised case report 
form.
Patient and public involvement
Patients or the public were not involved in the design, or conduct, 
or reporting or dissemination plans of our research.
Statistical analysis
Descriptive analysis of quantitative variables normally distributed 
were expressed as mean (number and %) and SD, whereas not- 
normally distributed variables were shown as median and IQR. 
Comparison of quantitative variables between two groups was 
performed using the t- test or non- parametric tests, according to 
the normality of the distribution. Comparison of proportions was 
performed using the Fisher’s exact test. Missed data were not 
imputed, and all the analysis was performed only on non- missing 
data. P value less than 0.05 was considered statistically significant. 
SPSS software (V.25; IBM) was used for statistical analysis.
RESULTS
Demographics and general characteristics of study population
Among 19 centres from seven European countries involved in 
the study, 12 registered at least one case. Of the 11 790 liver 
transplant recipient in regular follow- up overall, 91 patients 
were reported, of whom 57 were classified as confirmed cases 
and considered for statistical analysis (figure 1). Overall, 40 
recipients (70%) were male and median age (IQR) at diagnosis 
was 65 (57–70) years. Mean body mass index (BMI, kg/m2) was 
26.0±4.6, with 23 (43%) and 8 (14%) patients being overweight 
and obese, respectively. Eleven (19%) and 21 (37%) subjects 
were defined as very short- term and very long- term transplant 
recipients, respectively. Additionally, median time (IQR) from 
transplant to COVID-19 diagnosis was 6 (2–13) years, and 32 
(56%) patients had been transplanted more than 5 years before 
COVID-19 diagnosis. Characteristics related to indication for 
liver transplantation and underlying liver disease are summarised 
in table 1. With regard to comorbidities, 21 (37%) and 10 (18%) 
patients had one and more than one cardiovascular (CV) disease, 
respectively. In terms of CV risk factors, 32 (56%) recipients had 
arterial hypertension, and 21 (37%) diabetes mellitus, while 7 
(12%) were active or former smokers. Sixteen (28%) patients 
had chronic kidney disease. Furthermore, 24 (42%) subjects 
had a clinical history of neoplasia (20 with hepatocellular carci-
noma (HCC)), which was active in 5 (9%) patients. Concomitant 
respiratory diseases were found in 13 (23%) patients. Only one 
patient was HIV positive. Concerning pharmacological therapy 
for CV prevention, 13 (23%) recipients were on ACE inhibitors 
or sartans, while 9 (16%) were on low- dose aspirin.
Table 4 Baseline immunosuppression characteristics and modification during the infection
Baseline immunosuppression therapy Overall, n (%) No modification, n (%) Reduction, n (%) Discontinuation, n (%)
Single agent
CNIs 16 (28) 12 (75) 2 (12.5) 2 (12.5)
  Cyclosporine 3 (5) 2 (67) 0 1 (33)
  Tacrolimus 13 (29) 10 (77) 2 (15) 1 (8)
mTORi 2 (4) 1 (50) 0 1 (50)
  Everolimus 1 (2) 1 (100) 0 0
  Sirolimus 1 (2) 0 0 1 (100)
MMF 2 (3) 0 0 1 (100)
Steroid 1 (2) 1 (100) 0 0
Two or more agents
CNIs+MMF 21 (37) 7 (33) 6 (29) 8 (38)
  CNIs – – 5 1
  MMF – – 1 7
CNIs+mTORi 3 (5) 1 (33.3) 1 (33.3) 1 (33.3)
  CNIs – – 1 0
  mTORi – – 0 1
CNIs+steroids 9 (16) 1 (11.2) 4 (44.4) 4 (44.4)
  CNIs – – 4 4
  Steroids – – 0 0
CNIs+AZA 1 (2) 1 (100) 0 0
mTORi +MMF 2 (3) 1 (50) 0 1 (50)
  mTOR – – 0 1
  MMF – – 0 0
AZA, azathioprine; CNIs, calcineurin inihibitors, including cyclosporine and tacrolimus; MMF, mycophenolate mofetil; mTORi, mammalian target of rapamycin inhibitor, including 
sirolimus and everolimus.
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When we considered very- long term recipients in terms of 
comorbidities, CV disease (57% vs 25%, respectively; p=0.023) 
and arterial hypertension (76% vs 44%; p=0.028) were signifi-
cantly more frequent.
Presentation of COVID-19 in liver transplant patients
At the time of diagnosis, the most commonly self- reported symp-
toms were fever (44 patients, 79%), cough (31 patients, 55%), 
dyspnoea (26 patients, 46%), fatigue or myalgia (32 patients, 
56%), anosmia or dysgeusia (4 patients, 7%), as well as GI symp-
toms (18 patients, 33%). Patients who experienced the latter 
often had more than one GI symptom, diarrhoea being the most 
frequently reported (16 patients). Other unspecific symptoms 
included loss of appetite (four patients), headache (one patients) 
and sore throat (one patient), while confusion and delirium were 
reported in two hospitalised patients.
When long- term and short- term recipients were compared in 
terms of symptoms at presentation, fever (91% vs 63%, respec-
tively; p=0.019) and dyspnoea (59% vs 29%; p=0.032) were 
significantly more frequent among long- term recipients.
When very short- term recipients were considered, fever 
(50% vs 85%, respectively; p=0.045) and cough (27% vs 62%, 
p=0.048) were significantly less prevalent (table 2).
In the entire population, the diagnosis of SARS- CoV-2 infec-
tion was confirmed by NAAT positivity in nasopharyngeal 
swab, while one additional patients received BAL. Concerning 
radiological findings, CT scan and pulmonary radiography 
showed typical features of the disease in 24 (43%) and 23 (40%) 
cases, respectively.
The main laboratory findings are summarised in table 3. Four 
patients (8%) displayed relevant increase in liver enzymes (AST 
and/or ALT>2 × ULN). Conversely, median (IQR) leucocytes, 
lymphocytes and thrombocytes were 4.5 (3.3–6.0)×1000/
µL, 0.79 (0.40–1.10)×1000/µL and 160 (91–268)×1000/μL, 
respectively.
Concomitant bacterial infection was described in nine patients 
(16%). Three (6%) of them were defined suspected, since no 
confirmatory positive cultures were available, although clinical 
and laboratory findings were suggestive (symptomatic urinary 
infection, cholangitis and pulmonary coinfection) and six (11%) 
cases were defined as confirmed (positive blood culture). Gram- 
positive concomitant infection was found in three patients, while 
one patient resulted to be infected by Gram- negative strains and 
two subjects by both Gram- positive and Gram- negative strains. 
The most common Gram- negative strains belonged to Entero-
bacteriaceae (two Escherichia coli, one Enterobacter cloacae), 
whereas between Gram- positive strains enterococci were the 
most reported.
Management of immunosuppression therapy and COVID-19 
therapy
Baseline immunosuppression therapy and its management are 
described in table 4. Overall, reduction was observed in 22 
(39%) patients, and complete discontinuation was reported in 
4 cases (7%). Considering individual therapies, antimetabolites 
were the most frequently discontinued drugs (18%), whereas 
calcineurin inhibitors (CNIs) were the most frequently reduced 
ones (16%).
Concerning specific therapy for COVID-19, 19 (35%) patients 
received steroids, 22 (44%) hydroxychloroquine and 5 (9%) 
antivirals, including lopinavir/ritonavir (3 patients), darunavir/
cobicistat and remdesivir. Only one patient was treated with 
tocilizumab, while two more patients were on immunomodula-
tory therapies because of concomitant comorbities (one on ritux-
imab for active lymphoma and the other one on ruxolitinib for a 
graft vs host disease). Overall, 35 (63%) and 16 (29%) subjects 
received at least one and more than one antibiotic drug, respec-
tively. Of those, 15 (27%) were treated with azithromycin as part 
of the standard care of COVID-19 therapy in some centres.24
As for respiratory support, oxygen therapy was required in 
more than half of the patients (30, 54%). Of those, the majority 
required only oxygen therapy through nasal cannula (18 patients, 
32%), whereas 8 (14%) subjects received high- flow oxygen. 
Four (7%) patients required intubation and invasive mechanical 
ventilation (table 5).
Clinical outcome in liver transplant patients with COVID-19
Overall, 16 (28%, 95% CI 17% to 42%) patients received 
outpatient care for COVID-19, while 41 (72%, 95% CI 59% to 
83%) subjects were hospitalised, with a median (IQR) hospital 
stay duration of 10 days (7–22). Among hospitalised recipients, 
4 (10%, 95% CI 3% to 23%) were admitted to the ICU and 
required invasive mechanical ventilation, while 11 (19%, 95% 
CI 10% to 32%) developed ARDS. Death was registered in seven 
cases (12%, median time from transplant to death was 6 years, 
IQR 3–13), all of whom were hospitalised with ARDS. Overall, 
case fatality rate was 12% (95% CI 5% to 24%) in our popu-
lation, which increased to 17% (95% CI 7% to 32%) among 
hospitalised patients. General characteristics of patients who did 




Steroids (for COVID-19) 19 (35)
Antibiotics 35 (63)
  Azitromycin 15 (27)
  >1 antibiotic 16 (29)
Antivirals 5 (9)
  Lopinavir/ritonavir 3 (5)
  Darunavir/cobicistat 1 (2)
  Remdesivir 1 (2)
Immunomodulator 3 (5)
  Tocilizumab 1 (2)
  Rituximab 1 (2)
  Ruxolitinib 1 (2)
Hydroxychloroquine 24 (44)
Oxygen therapy (higher intensity), n (%)
Overall 30 (54)
  Nasal cannula 18 (32)
  Non- invasive ventilation 8 (14)




ICU admission 4 (7)
Hospitalisation (no ICU) 37 (65)
  Need for rehabilitation 7 (17)
Duration of hospitalisation, median (IQR)
Hospital stay 10 (7–22)
  ICU stay 16 (10–19)
Rehab stay 14 (11–15)
ARDS, acute respiratory distress syndrome; ICU, intensive care unit.
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not survive, of those with ARDS and of those who were hospi-
talised are summarised in tables 6 and 7. Five out of the seven 
patients who died had a history of cancer, of whom three had an 
active cancer at moment of the diagnosis of COVID-19. More-
over, 9 out of 11 patients with ARDS had a clinical history for 
cancer. Median (IQR) lymphocyte and platelet counts (×1000/
μL) were significantly lower (0.49 (0.30–0.60) vs 0.80 (0.52–
1.18), p=0.030; 93 (79-110) vs 170 (104–273), p=0.044, 
respectively) in the group of patients who did not survive.
DISCUSSION
In this observational prospective multicentre study, we report 
the characteristics, early outcome and management of the 
COVID-19 outbreak on the largest European cohort of liver 
transplant patients with confirmed SARS- CoV-2 infection up to 
date. Case fatality rate of the overall study population was 12% 
(95% CI 5% to 24%), whereas that of the hospitalised patients 
was 17% (95% CI 7% to 32%). This latter is in line with that 
of the general population, as reported by most of the largest 
studies, where the in- hospital case fatality rate ranges from 15% 
to 22%.1 25 26 All the patients who died, except one, were men. 
CV disease, obesity, arterial hypertension, diabetes mellitus and 
chronic kidney disease, although well represented in our popu-
lation, were not over- represented in the group with adverse 
outcomes. A clinical history of neoplasia, especially an active 
cancer at the moment of the diagnosis, was frequently found 
in the group with a worse prognosis. Recently transplanted 
patients presented with less fever and respiratory- related symp-
toms than patients who were transplanted for more than 1 and 
5 years, respectively. Among laboratory data, lymphocytopenia 
and thrombocytopenia were more frequent in patients who 
died. Alteration in liver enzymes was mild and rarely observed, 
although mostly found in hospitalised patients. Whether the 
immunosuppression was decreased or left unchanged had no 
impact on outcome.
Our study suggests that, despite well- described risk factors for 
poor outcome of COVID-19 infection are highly represented in 
our cohort, COVID-19 liver transplant patients show a clinical 
course not necessarily more severe to that observed in non- liver 
transplant patients affected by COVID-19.25–27 Publications 
pooling patients with different organ transplanted reported 
worse outcomes (in- hospital case fatality rate 24%–27%).11 13 
Another publication merging surveys from European and Amer-
ican centres with a smaller sample than our prospective study 
reported 9 deaths among 39 liver transplant patients.28 Like 
others, we find that male patients are more prone to develop 
ARDS29 and have a more severe outcome.25 Although highly 
frequent in our cohort, CV and metabolic comorbidities were not 
over- represented in patients with poor outcomes.25 26 History of 
previous or active cancer, such as being transplanted for HCC 
or having cancer at the moment of the COVID-19 diagnosis, 
was associated with a poor outcome. This is in agreement with 
a national Chinese report on over 2000 confirmed COVID-19 
cases with a history of cancer, showing them having higher risk 
to contract COVID-19 and poorer outcome than individuals 
without cancer.30 31
Concerning clinical presentation, patients transplanted for less 
than 5 years exhibited less frequently fever and dyspnoea. This 
may suggest higher immunosuppression attenuates COVID-19 
typical clinical symptoms. GI manifestations were common 
(33%) in our series, which is in line with the 29% reported in 
solid organ transplant recipients in Spain.11
Lymphopenia has been reported to be predictive of poor 
outcome in non- transplanted COVID-19 patients.29 32 A similar 
trend was found also in our cohort of liver transplant patients.
One of the key questions in the management of liver transplant 
patients affected with COVID-19 concerns the management of 
the immunosuppression.33 In our cohort, the immunosuppres-
sion was reduced in 39% of the patients and discontinued in 
7%. Mycophenolate mofetil was the most discontinued therapy. 
The majority of the patients with COVID-19 who did not need 
a hospitalisation were kept on their usual immunosuppres-
sive regimen. Although some reports want to suggest a poten-
tial positive role of tacrolimus as antiviral in the treatment of 
Table 6 Characteristics of liver transplant recipients died because of COVID-19







1 M 67 Caucasian 27.8 History of renal tumour Fever, cough, dyspnoea CNIs alone NIMV No
No change
2 M 78 Caucasian 23.1 History of PTLD Fever, cough, dyspnoea CNIs alone NIMV No
CV disease No change
Diabetes
CKD
3 M 75 Caucasian 25.1 Active tumour: HCC 
recurrence
Dyspnoea, CNIs alone NIMV No
CV disease Fatigue/myalgia No change
Arterial hypertension
4 M 55 Caucasian 21.6 – Fever, dyspnoea CNIs+steroids NIMV No
Only CNIs discontinuation
5 M 70 Caucasian 28.5 Active tumour: HCC 
recurrence
Fever, dyspnoea CNIs+steroids IMV Yes
Arterial hypertension Only CNIs discontinuation
6 M 66 Caucasian 23.8 Active tumour: PTLD Fever, cough, fatigue/
myalgia, GI symptoms
Steroids IMV Yes
Arterial hypertension No change
7 F 79 Caucasian 21.3 CV disease Fever, dyspnoea, 
fatigue/myalgia




CKD, chronic kidney disease; CNIs, calcineurin inhibitors; CV, cardiovascular; F, female; IMV, invasive mechanical ventilation; M, male; MMF, mycophenolate mofetil; NC, nasal cannula; NIMV, non- invasive mechanical 
ventilation; PTLD, post- transplant lymphoproliferative disorder.
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human coronaviruses,34 since 88% of our patients were treated 
with CNIs, it was not possible to assess any specific effect of this 
therapy.
Our study has limitations. All the participating centres 
are European. It will be important to have similar prospec-
tive studies from other continents. We limited our analysis 
to the patients with a positive reverse transcription PCR for 
SARS- CoV-2. We did not include patients with typical presen-
tation but without a microbiological confirmation due to lack 
of testing capacity. On the other hand, the NAAT assay as the 
recommended confirmatory test has a sensitivity in the order 
of 71%,35 and this could be lower in immunosuppressed popu-
lation.13 Moreover, although liver transplant patients were 
generally well instructed to contact their transplant centre as 
far as COVID- like symptoms appeared, we cannot exclude 
a global underestimation of the total number of COVID-19 
infections in this population.
Our study has strengths. It is, at the time of writing, the largest 
prospective study of liver recipient patients affected by COVID-
19. It is by design not a survey but a prospective acquisition of 
data approved by local ethics committees.
In conclusion, in this European multicentre prospective study 
of liver transplant recipients, COVID-19 is associated with an 
overall and in- hospital case fatality rate of 12% (95% CI 5% 
to 24%) and 17% (95% CI 7% to 32%), respectively. Patients 
infected early after liver transplantation did not have a worse 
outcome and tend to have less symptoms. A history of cancer 
was more frequent in patients with poorer outcome.
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